Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3358300 | 0.91 | HPGD (0.50) | HPGDKCNA5KMT2ALMNAPOLB | |
| SCHEMBL1429119 | 0.89 | KMT2A (0.60) | HPGDKMT2ALMNAALDH1A1TACR1 | |
| SCHEMBL29174151 | 0.88 | MEN1 (0.49) | HPGDKCNA5KMT2ALMNATACR1 | |
| SCHEMBL29174146 | 0.87 | MAPT (0.50) | HPGDKCNA5KMT2ALMNAPOLB | |
| SCHEMBL28677834 | 0.87 | KCNA5 (0.52) | HPGDKCNA5KMT2ALMNAPOLB | |
| SCHEMBL3358387 | 0.87 | CTSA (0.49) | HPGDKCNA5KMT2APOLBALDH1A1 | |
| SCHEMBL12473253 | 0.86 | KCNA5 (0.65) | HPGDKCNA5KMT2APOLBALDH1A1 | |
| SCHEMBL7995142 | 0.86 | ALDH1A1 (0.67) | HPGDKCNA5KMT2APOLBALDH1A1 | |
| SCHEMBL24661003 | 0.85 | KCNA5 (0.52) | HPGDKCNA5KMT2APOLBALDH1A1 | |
| SCHEMBL6306108 | 0.85 | MTNR1A (0.63) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0641208-B1 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO INC (US) | 2000-08-02 | — | — | EP | claimed |
| EP-0778284-A2 | New 7-beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0641208-A4 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS. | MERCK & CO INC (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0641208-A1 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| WO-1993023048-A1 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| CN-110914241-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2021231778-A1 | CORONAVIRUS PROTEASE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210102083-A1 | THERMOCHROMIC PIGMENT COMPOSITIONS | SOCIETE BIC (FR) | 2021-04-08 | — | — | US | disclosed |
| US-10561666-B2 | Amido compounds as RORγt modulators and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-02-18 | — | — | US | disclosed |
| US-10351506-B2 | Purified plasticizers, production and use | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190031593-A1 | Purified Plasticizers, Production and Use | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-01-31 | — | — | US | disclosed |
| EP-0641208-B1 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO INC (US) | 2000-08-02 | — | — | EP | disclosed |
| US-5620986-A | TREATS BENIGN PROSTATIC HYPERTROPHY, SEBORRHEA, FEMALE HIRSUTISM, AND MALE AND FEMALE PATTEN BALDNESS | MERCK & CO., INC. (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0641208-A4 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS. | MERCK & CO INC (US) | 1995-08-30 | — | — | EP | disclosed |
| EP-0641208-A1 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5312828-A | Substituted imidazoles having angiotensin II receptor blocking activity | SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA | 1994-05-17 | — | — | US | disclosed |
| WO-1993023048-A1 | 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351506-B2 | Purified plasticizers, production and use | ALKBH3, FTO, ALK | HPGD 2824/4885KCNA5 3761/4885KMT2A 416/4885 |
| US-20210102083-A1 | THERMOCHROMIC PIGMENT COMPOSITIONS | TYR, MITF, MC1R | HPGD 1357/4885KCNA5 1198/4885KMT2A 3087/4885 |
| US-20190031593-A1 | Purified Plasticizers, Production and Use | ALKBH3, FTO, ALK | HPGD 2824/4885KCNA5 3761/4885KMT2A 416/4885 |
| US-10561666-B2 | Amido compounds as RORγt modulators and uses thereof | RORB, RORA, RORC | HPGD 1073/4885KCNA5 4414/4885KMT2A 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.